Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $1.5 billion.
- Biomarin Pharmaceutical's Long-Term Deferred Tax fell 141.56% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 141.56%. This contributed to the annual value of $1.5 billion for FY2024, which is 365.14% down from last year.
- As of Q3 2025, Biomarin Pharmaceutical's Long-Term Deferred Tax stood at $1.5 billion, which was down 141.56% from $1.4 billion recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year Long-Term Deferred Tax high stood at $1.5 billion for Q1 2024, and its period low was $1.4 billion during Q2 2025.
- For the 5-year period, Biomarin Pharmaceutical's Long-Term Deferred Tax averaged around $1.5 billion, with its median value being $1.5 billion (2024).
- Per our database at Business Quant, Biomarin Pharmaceutical's Long-Term Deferred Tax soared by 16470.6% in 2021 and then plummeted by 763.65% in 2025.
- Biomarin Pharmaceutical's Long-Term Deferred Tax (Quarter) stood at $1.5 billion in 2021, then rose by 3.81% to $1.5 billion in 2022, then increased by 2.68% to $1.5 billion in 2023, then dropped by 3.65% to $1.5 billion in 2024, then grew by 1.33% to $1.5 billion in 2025.
- Its Long-Term Deferred Tax stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.